Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05922501 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05922501 · ClinicalTrials.gov record · last posted 2026-01-14

Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma

Study acronym: ISABELA
StatusRecruiting
PhasePhase 2
Started2024-05-31
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The main goal of this phase II study is to evaluate the overall response rate of isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma. The study drugs provided for research purposes are isatuximab and belantamab mafodotin.

Amendment record 2 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 2 times since 2023-06-19; most recent amendment 2026-01-12. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2026-01-12
Status change Not Yet Recruiting→Recruitingv2
Trial Details
NCT Number NCT05922501
Lead Sponsor Massachusetts General Hospital
Collaborators: Sanofi, GlaxoSmithKline
Conditions Relapsed Cancer, Refractory Multiple Myeloma, Multiple Myeloma
Enrollment 50 participants
Start Date 2024-05-31
Primary Completion 2028-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-14